ManufacturingNAICS 325414

Sell a Biotech Manufacturing business

US manufacturing M&A has benefited from reshoring, defense procurement, and infrastructure spending. the FDA inspection history and capability are the defining moats.

Get matched to a broker Run instant valuation

What moves the multiple

Value drivers in biotech manufacturing

Manufacturing businesses sit within a broad multiple band. These are the specific factors that determine where you land inside it.

Biotech Manufacturing-specific

Certifications: ISO 9001, AS9100, ITAR, FDA, MedAccred

Repeat customer base with multi-year purchase orders

Domestic supply-chain positioning (reshoring beneficiary)

Automated / cellular production flow

Documented quality management system with traceability

Biotech Manufacturing operations and business context

Diligence risks

What buyers scrutinize

Every category has structural risks that buyers double-click on. Preparing responses in advance keeps them out of the purchase-price adjustment column.

Biotech Manufacturing-specific risk

Biotech manufacturing has intense FDA and cGMP compliance exposure with material 483/warning-letter risk; buyers require deep quality-system diligence.

Customer concentration above 20% (common in job-shop manufacturing)

Legacy machinery capex catch-up requirement

Skilled machinist / operator labor shortage

Environmental and OSHA compliance exposure

Active buyers

Who buys biotech manufacturing businesses

Buyer archetype depends on scale. Sub-$1M SDE draws individuals and search funds. $1–3M SDE opens platform and strategic interest. $3M+ EBITDA is full LMM buyer territory.

Recent acquirer activity

Catalent (acquired by Novo Holdings), Lonza, Thermo Fisher, and PE platforms (Ampersand Capital, Water Street) drive CDMO consolidation.

Vertical integrator

Strategic

Customer- or supplier-side strategic acquirers pay premium multiples for margin capture and supply-chain security.

Industrial PE platform

PE Platform

Warburg Pincus, KPS Capital, Blue Wolf, Kohlberg, AEA Investors, Wynnchurch actively bid on $3M+ EBITDA operators as platforms or bolt-ons.

Family office

Family Office

Industrials-focused family offices favor stable-margin, capex-light manufacturers as long-hold assets.

Browse buyer registry Who buys my business? tool

Playbook

Exit playbook — manufacturing

The single largest driver of purchase-price outcome is preparation depth. These are the levers that move the needle in manufacturing exits.

1
Diversify customer concentration below 20% before going to market
18-24 months pre-sale
Customer concentration is the single biggest valuation lever in manufacturing M&A. A dedicated year-one push to add customers materially lifts the multiple.
2
Address deferred maintenance capex before diligence
12-18 months pre-sale
Buyers under-adjust for capex-catch-up. Complete or explicitly document the maintenance backlog to avoid a purchase-price haircut.
3
Get certifications current and traceable
6-12 months pre-sale
Lapsed ISO / AS9100 / FDA registrations kill deals. Confirm all certifications are current and audit trails are complete.
4
Formalize quality management system documentation
12-18 months pre-sale
Reviewed QMS with SOPs and traceability is a required diligence element for any strategic or PE buyer.

Topical cluster

Related industries

Owners of biotech manufacturing businesses often also operate — or acquire — businesses in adjacent verticals.

Pharmaceutical Contract Manufacturing

SDE 4x–6.5x · EBITDA 9x–15x

Medical Device Manufacturing

SDE 4x–6.5x · EBITDA 8x–14x

Chemical Manufacturing

SDE 3.5x–6x · EBITDA 7x–12x

Contract Manufacturing

SDE 3.5x–5.5x · EBITDA 5.5x–9.5x

Adhesive & Sealant Manufacturing

SDE 3.5x–5.5x · EBITDA 6.5x–10.5x

Aerospace Manufacturing

SDE 4x–6.5x · EBITDA 7x–12x

All manufacturing industries

FAQ

Biotech Manufacturing exits, answered

What is a biotech manufacturing business worth?

Owner-operator biotech manufacturing businesses trade at 4x–6.5x SDE for typical $500K–$3M SDE ranges. At $3M+ EBITDA scale the same operators sell at 9x–16x EBITDA. Multiples in this category are ebitda-based and data-sourced from GF Data Q4 2024 Manufacturing + PitchBook Industrials 2025. Where you land in the range is driven by growth trajectory, revenue mix, customer concentration, and management-team depth beyond the owner.

Who buys biotech manufacturing businesses right now?

Catalent (acquired by Novo Holdings), Lonza, Thermo Fisher, and PE platforms (Ampersand Capital, Water Street) drive CDMO consolidation. Active buyer archetypes in manufacturing include Vertical integrator, Industrial PE platform, Family office. Which of these bids for your business depends on scale — sub-$1M SDE is typically individual or search-fund territory, $1-3M SDE opens up PE platforms and strategics, and $3M+ EBITDA gets full LMM buyer attention.

What drives multiple expansion in biotech manufacturing?

Biotech CDMOs with FDA-inspected cGMP facilities and cell-and-gene-therapy or biologics-fill-and-finish capability trade at premium multiples — the FDA inspection history and capability are the defining moats. Beyond the industry-specific factor, the universal drivers in manufacturing are certifications: iso 9001, as9100, itar, fda, medaccred; repeat customer base with multi-year purchase orders; domestic supply-chain positioning (reshoring beneficiary).

What are the biggest risks in selling a biotech manufacturing business?

Biotech manufacturing has intense FDA and cGMP compliance exposure with material 483/warning-letter risk; buyers require deep quality-system diligence. Buyers in this category also standardly scrutinize customer concentration above 20% (common in job-shop manufacturing) and legacy machinery capex catch-up requirement. Addressing these in advance in a well-prepared CIM materially reduces retrade risk during diligence.

What revenue range makes biotech manufacturing sellable to a professional buyer?

Typical transaction range for biotech manufacturing is $3.0M–$100M in annual revenue. Below that, buyer pool narrows to individual and small-search-fund. Above that, PE platforms and strategics dominate. NAICS code 325414 — buyers screen by NAICS in most deal sources.

How long does it take to sell a biotech manufacturing business?

From the day you engage a broker to close, expect 6–12 months for a well-prepared business in manufacturing. The prep work — financial cleanup, addbacks documentation, key-employee retention agreements, real estate lease sorting — is where 3-6 months of the timeline hides. Starting that early is what separates a full-multiple exit from a discounted one.

Data provenance: Valuation multiples anchored in GF Data Q4 2024 Manufacturing + PitchBook Industrials 2025. Buyer names and platforms are cited from public M&A disclosures, SEC filings, and press releases. Nothing on this page is fabricated. Multiples are whole-market ranges — your specific business will price above or below based on the drivers and risks above.

Published June 30, 2025 · Updated July 11, 2026

Ready to explore an exit?

Get matched to a biotech manufacturing specialist.

Answer three quick questions. We surface vetted brokers with real biotech manufacturing deal experience.

Get matched Run valuation instead